AU721290B2 - Method for treating migraine pain - Google Patents

Method for treating migraine pain Download PDF

Info

Publication number
AU721290B2
AU721290B2 AU25845/97A AU2584597A AU721290B2 AU 721290 B2 AU721290 B2 AU 721290B2 AU 25845/97 A AU25845/97 A AU 25845/97A AU 2584597 A AU2584597 A AU 2584597A AU 721290 B2 AU721290 B2 AU 721290B2
Authority
AU
Australia
Prior art keywords
olanzapine
migraine pain
pct
pain
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU25845/97A
Other languages
English (en)
Other versions
AU2584597A (en
Inventor
Harlan E Shannon
Daniel E. Womer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2584597A publication Critical patent/AU2584597A/en
Application granted granted Critical
Publication of AU721290B2 publication Critical patent/AU721290B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU25845/97A 1996-03-25 1997-03-24 Method for treating migraine pain Ceased AU721290B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1412796P 1996-03-25 1996-03-25
US60/014127 1996-03-25
PCT/US1997/004471 WO1997035582A1 (en) 1996-03-25 1997-03-24 Method for treating migraine pain

Publications (2)

Publication Number Publication Date
AU2584597A AU2584597A (en) 1997-10-17
AU721290B2 true AU721290B2 (en) 2000-06-29

Family

ID=21763694

Family Applications (1)

Application Number Title Priority Date Filing Date
AU25845/97A Ceased AU721290B2 (en) 1996-03-25 1997-03-24 Method for treating migraine pain

Country Status (17)

Country Link
US (1) US5929070A (pt)
EP (1) EP0932407A4 (pt)
JP (1) JP2001508759A (pt)
KR (1) KR20000004966A (pt)
CN (1) CN1106196C (pt)
AU (1) AU721290B2 (pt)
BR (1) BR9708145A (pt)
CA (1) CA2250186A1 (pt)
CZ (1) CZ298398A3 (pt)
EA (1) EA000769B1 (pt)
IL (1) IL126063A (pt)
NO (1) NO984432L (pt)
NZ (1) NZ332037A (pt)
PL (1) PL329221A1 (pt)
UA (1) UA44838C2 (pt)
WO (1) WO1997035582A1 (pt)
YU (1) YU42098A (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9708254A (pt) * 1996-03-25 1999-08-03 Lilly Co Eli Método para o tratamento da dor
AU721338B2 (en) * 1996-03-25 2000-06-29 Eli Lilly And Company Method for treating pain
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
WO2004047841A1 (en) * 2002-11-26 2004-06-10 Alexza Molecular Delivery Corporation Treatment of headache with antipsychotics delivered by inhalation
AU2003294470B2 (en) 2002-11-26 2009-09-17 Alexza Pharmaceuticals, Inc. Use of loxapine and amoxapine for the manufacture of a medicament for the treatment of pain
US20040234699A1 (en) 2003-05-21 2004-11-25 Alexza Molecular Delivery Corporation Methods of controlling uniformity of substrate temperature and self-contained heating unit and drug-supply unit employing same
US7829700B2 (en) * 2004-09-06 2010-11-09 Shasun Chemicals And Drugs Limited Process for preparation of a pharmaceutically pure polymorphic form I of Olanzapine
US20080216828A1 (en) 2007-03-09 2008-09-11 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
US10736842B2 (en) 2014-06-25 2020-08-11 Synergia Bio Sciences Private Limited Pharmaceutical oil-in-water nano-emulsion
US11400048B2 (en) 2014-06-25 2022-08-02 Synergia Bio Sciences Private Limited Pharmaceutical oil-in-water nano-emulsion

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT100602A (pt) * 1991-06-21 1993-09-30 Smithkline Beecham Plc Uso de derivados de tetra-hidrobenzazepinas, derivados de tetra-hidrobenzazepinas,sua preparacao e composicoes farmaceuticas que os contem
DK206591D0 (da) * 1991-12-23 1991-12-23 Lundbeck & Co As H Behandling af psykoser
TW268005B (pt) * 1992-05-29 1996-01-11 Lilly Industries Ltd
WO1995024200A1 (en) * 1994-03-11 1995-09-14 Eli Lilly And Company Method for treating 5ht2b receptor related conditions
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use

Also Published As

Publication number Publication date
US5929070A (en) 1999-07-27
CN1106196C (zh) 2003-04-23
UA44838C2 (uk) 2002-03-15
EP0932407A4 (en) 2002-04-24
CN1219876A (zh) 1999-06-16
AU2584597A (en) 1997-10-17
CZ298398A3 (cs) 1999-06-16
YU42098A (sh) 1999-09-27
BR9708145A (pt) 1999-07-27
EP0932407A1 (en) 1999-08-04
WO1997035582A1 (en) 1997-10-02
JP2001508759A (ja) 2001-07-03
PL329221A1 (en) 1999-03-15
NZ332037A (en) 2001-01-26
IL126063A (en) 2002-04-21
NO984432L (no) 1998-11-24
NO984432D0 (no) 1998-09-23
KR20000004966A (ko) 2000-01-25
EA000769B1 (ru) 2000-04-24
CA2250186A1 (en) 1997-10-02
EA199800864A1 (ru) 1999-02-25
IL126063A0 (en) 1999-05-09

Similar Documents

Publication Publication Date Title
US5945416A (en) Method for treating pain
AU721290B2 (en) Method for treating migraine pain
US6258807B1 (en) Method for treating pain
AU734011B2 (en) Method for treating bipolar disorder
AU709181B2 (en) Method for treating autism
AU719517B2 (en) Method for treating excessive aggression
CA2248758A1 (en) Method for treating insomnia
CA2248905A1 (en) Method for treating bipolar disorder

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)